| | | | | 请输入关键字查询 | | | Q搜索 | | --- | --- | --- | --- | --- | --- | --- | --- | | 首页 | 时政要闻 医保新闻 | 机构设置 政策法规 信息公开 | | | 统计数据 | 机关党建 | 互动交流 | | 首页> 政府信息公开> 法定主动公开内容> 政策法规 | | | | | | 加力促地名· ■■■■■■■■ | | | 名称: | | 国家医保局 人力资源社会保障部关于印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创 | | | | | | | | | 新药品目录》(2025年) 的通知 | | | | | | | 索引号: | 2025-02-00027 | 发文字号: 医保发〔2025〕33号 | | | | | | | 发布日期: | 2025-12-07 | 发布机构: | | | | | | | | | 国家医保局 人力资源社会保障部 | | | | | | | | | | 关于印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》 (2025年) 的通知 | ...

Core Viewpoint - Tibet Pharmaceutical (600211) has seen a positive market response following the announcement that its subsidiary's product, Xinhuasuan, has been included in the National Medical Insurance Drug List for 2025, which is expected to enhance future sales and operational development [1][2]. Group 1: Company Performance - As of December 8, 2025, Tibet Pharmaceutical's stock closed at 41.97 CNY, up 0.65% from the previous trading day, with a total market capitalization of 13.528 billion CNY [1]. - The stock opened at 41.78 CNY, reached a high of 42.19 CNY, and recorded a low of 41.78 CNY, with a trading volume of 96.8223 million CNY and a turnover rate of 0.71% [1]. Group 2: Product and Market Impact - The product Xinhuasuan, a recombinant human brain natriuretic peptide injection, is primarily used for the short-term treatment of acute decompensated heart failure and is limited to use in secondary and higher medical institutions [1]. - In 2024, Xinhuasuan is projected to generate sales revenue of 2.433 billion CNY, accounting for 86.89% of the company's main business revenue; in the first half of 2025, it is expected to generate 1.456 billion CNY, representing 88.36% of the revenue [1]. - The inclusion of Xinhuasuan in the regular drug list is anticipated to have a positive impact on the company's future sales and operational growth [1].

格隆汇12月8日丨轩竹生物-B(02575.HK)宣布，公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)首 次纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。2025国家基本医保目录将于 2026年1月1日正式执行。 本次医保谈判结果有助于公司进一步提高轩悦宁?在患者中的可负担性和可及性，有利于进一步推动该 药物的市场推广、提升销售规模，对公司的长期经营发展具有积极影响。公司将积极配合推进医保政策 落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及性。 ...